Chesapeake VA Business VoIP Telephone Systems & Communication Services Launched

South Bay Communications, a Chesapeake telecommunications company, announced updated office communication solutions. Offering analog, VoIP and cloud-based systems, the company provides the latest ESI phone models for businesses of all sizes, working with licensed experts to ensure high standards of quality and reliability.

Chesapeake, United States - September 13, 2017 /PressCable/ —

South Bay Communications & Security, a professional telecommunications and security company based in Chesapeake, Virginia, launched updated office telephone systems for businesses looking for the latest communication solutions. The company offers ESI telephone system installation, as well as full support and transition facility for Toshiba users.

More information can be found at http://southbaycomm.com/esi-telephone-systems-chesapeake.

Professional telephone systems are essential for companies looking to optimize their internal and external communications. While landline phone systems are still popular, VoIP is attracting more and more clients interested in higher portability and overall improved performance.

South Bay Communications offers complete office telephone system installation for businesses interested in state-of-the-art communication technology.

The Chesapeake telecommunications company has more than 15 years of experience providing complete ESI telephone systems for business in various industries.

A leader in office telecommunications, ESI has implemented cutting-edge technologies in mobile telephony since 1987, launching a wide range of high-performance systems for various office needs.

South Bay Communications offers the latest desktop smartphones, the ESI ePhone 7 and 4 models. The new office phones offer all the benefits of standard models while also providing the superior connectivity, interactivity and communication features found in the latest smartphones.

On-premises business phones are also available, from the entry-level ESI 30D Business Phone to the more complex ESI 60 model.

Finally, the company also provides ESI phones built for integrated communication within the ESI Cloud PBX system. These models allow communication with multiple devices, offering clients synchronized performance on both phones and computer dashboards.

The latest updates are part of South Bay Communications’ continuous efforts to offer high standards of professionalism and customer satisfaction for clients in Chesapeake and the surrounding area. Debbie Bowman of Dominion Psychiatric Associates, a client of South Bay Communications, declared:

“I truly value professional business relationships and never in the more than fifteen years that I have known the Bruce brothers have I had and issue that was not resolved or felt like my concerns as client were not being addressed. I can say that level of service is hard to come by in today’s me-centric business world and I appreciate the care and concern that South Bay gives to their client base.”

Interested parties can find more information by visiting the above-mentioned website.

Contact Info:
Name: Mark Rowan
Email: mrowan@southbaycomm.com
Organization: South Bay Communications & Security
Address: 820 Greenbrier Cir., Ste. 26, Chesapeake, VA 23320, United States
Phone: +1-757-523-9646

For more information, please visit http://www.southbaycomm.com

Source: PressCable

Release ID: 238925

Latest News

EU charges Merck KGaA, GE, Canon of misleading merger info

Sep 25, 2017

By Foo Yun CheeBRUSSELS (Reuters) - General Electric , German drugmaker Merck KGaA , and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals.The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules.While the charges will not affect the EU approvals of the deals, they could lead to fines up to 1 percent of global revenue for Merck KGaA and General Electric, and up to...

Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Sep 25, 2017

By Sam NusseyTOKYO (Reuters) - Konica Minolta Inc said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the Japanese firm's healthcare business as it seeks a leading position in precision medicine.The deal is the largest ever for the photocopier maker, which has been seeking to diversify away its office equipment business. It pulled out of cameras about a decade ago.Konica Minolta said its advanced imaging technology complemented privately held Ambry's genetic testing capabilities, with initial applications for combining the technologies seen in...

Oxford BioMedica wins big contract for Novartis cell therapy

Sep 25, 2017

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability.The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukemia that is expected to reach the market this year.A U.S. advisory panel will discuss the case for approving CTL019 at a meeting...

Novartis receives EU approval for Cosentyx label update

Sep 25, 2017

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday. (Reporting by Silke Koltrowitz)

FDA puts hold on Merck multiple myeloma trials after deaths

Sep 25, 2017

(Reuters) - Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.The rare setback for Keytruda sent Merck shares more than 1 percent lower.Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market. Bristol-Myers...

Search
Top News
You May Need To Know

About Us

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales@thehealthierweb.com